SynthesisFrontiers in pharmacology2026
Biologic therapy for Crohn's disease (2015-2025): a bibliometric analysis of global research trends and current status.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease (CD) is a chronic inflammatory bowel disease with rising global prevalence. Biologic agents have become the cornerstone of treatment for moderate-to-severe CD, yet the rapidly expanding literature makes systematic tracking of research trends challenging. This study presents a comprehensive bibliometric analysis to systematically map the research landscape of biologic therapy for CD from 2015 to 2025. Methods: Publications on biologic therapy for CD were retrieved from the PubMed, Web of Science Core Collection, and Scopus databases for the period from 1 January 2015 to 31 December 2025. To ensure consistency in interpretation and indexing across databases, only English-language articles were included. After deduplication using EndNote and manual screening, 15,828 eligible publications were included in the final analysis. Bibliometric and visualization analyses were performed using CiteSpace, VOSviewer, RStudio, and SCImago Graphica. Metrics including annual publication output, country contributions with centrality analysis (indicating a country's bridging role in international collaboration networks), institutional collaboration networks, author co-authorship patterns, keyword co-occurrence, cluster analysis, timeline visualization, and citation bursts were systematically examined. Results: The annual publication output showed a consistent upward trend. The United States (n = 4,505), China (n = 1,528), and Italy (n = 1,509) were the top three producers; Canada showed the highest centrality (0.93), reflecting its role as a key bridge in transnational collaborations. Keyword co-occurrence revealed a trilevel structure centered on CD, with "biological marker" and "biological product" appearing at near-equal frequencies. Eleven clusters were identified (Q = 0.5991, silhouette = 0.8053), and 25 citation bursts revealed a three-phase evolution from efficacy validation to strategy optimization. Conclusion: The bibliometric findings demonstrate that CD biologic therapy research has established a mature ecosystem, with shifting emphases toward biomarker-driven stratification and comparative effectiveness. Future priorities emerging from the data include individualized sequencing strategies, head-to-head comparisons with novel small-molecule agents, and expanded investigation in understudied populations such as adolescents and pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.